Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00SOE
|
|||
| Former ID |
DNC008988
|
|||
| Drug Name |
KSG-YEKLSSIESDV
|
|||
| Synonyms |
CHEMBL445253; KSG-YEKLSSIESDV
Click to Show/Hide
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C66H108N16O26
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)CNC(=O)C(CO)NC(=O)C(CCCCN)N
|
|||
| InChI |
1S/C66H108N16O26/c1-7-34(6)53(65(106)74-40(19-21-50(91)92)58(99)78-45(29-84)62(103)76-43(26-51(93)94)61(102)81-52(33(4)5)66(107)108)82-64(105)47(31-86)80-63(104)46(30-85)79-59(100)41(24-32(2)3)75-56(97)38(13-9-11-23-68)72-57(98)39(18-20-49(89)90)73-60(101)42(25-35-14-16-36(87)17-15-35)71-48(88)27-70-55(96)44(28-83)77-54(95)37(69)12-8-10-22-67/h14-17,32-34,37-47,52-53,83-87H,7-13,18-31,67-69H2,1-6H3,(H,70,96)(H,71,88)(H,72,98)(H,73,101)(H,74,106)(H,75,97)(H,76,103)(H,77,95)(H,78,99)(H,79,100)(H,80,104)(H,81,102)(H,82,105)(H,89,90)(H,91,92)(H,93,94)(H,107,108)/t34-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,52-,53-/m0/s1
|
|||
| InChIKey |
OYOJPGJCPOXGEB-QBAAMSOUSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Presynaptic density protein 95 (DLG4) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Hippo signaling pathway | |||
| Glutamatergic synapse | ||||
| Huntington's disease | ||||
| Cocaine addiction | ||||
| Panther Pathway | Huntington disease | |||
| Pathway Interaction Database | ErbB4 signaling events | |||
| Reactome | Trafficking of AMPA receptors | |||
| Unblocking of NMDA receptor, glutamate binding and activation | ||||
| CREB phosphorylation through the activation of CaMKII | ||||
| Ras activation uopn Ca2+ infux through NMDA receptor | ||||
| RHO GTPases activate CIT | ||||
| RAF/MAP kinase cascade | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| L1CAM interactions | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.